ÂÜÀòÂÒÂ×

Ben Bronstein is the current director at Aldeyra Therapeutics. Prior to this, they were the executive vice president of clinical development at Aclaris Therapeutics, Inc. from November 2017 to December 2018. Aclaris Therapeutics is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Prior to their time at Aclaris, Bronstein served as the chief medical officer (interim) at Sentien Biotechnologies, Inc. from April 2016 to December 2017. Sentien Biotechnologies is a company that focuses on actively treating acute kidney injury (acute renal failure) patients during continuous renal replacement therapy by supplementing patient blood with Mesenchymal Stromal Cell-derived secretions, a mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repair response.

Ben Bronstein attended the Questrom School of Business at Boston University, where they received their MBA with a focus in finance and marketing. Ben then attended Boston University School of Medicine, where they earned their MD. Finally, they completed their undergraduate studies at Boston University, earning an AB in biology with magna cum laude honors.